Results 81 to 90 of about 211,755 (262)
Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient
Hematology Reports, 2014 Acute myeloid leukemia (AML) is a hematological malignancy of myeloid progenitor cells that disrupt normal hematopoiesis. Current chemotherapy regimens result in complete remission in many cases; however, there exists no standard efficacious therapy for ...
Harry Ross Powers +4 more
doaj +1 more source
Therapeutic Silencing of Tmprss6 Reduces Iron‐Induced Inflammation and Prolongs Survival in MDS Mice
American Journal of Hematology, EarlyView.ABSTRACT Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic disorders characterized by ineffective hematopoiesis, cytopenias, and an increased risk of progression to acute myeloid leukemia (AML). Despite advances in supportive and targeted therapies, disease‐modifying interventions remain limited.
Shahla Vilcassim +13 more
wiley +1 more source
Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study
American Journal of Hematology, EarlyView.ABSTRACT Cancer care is often complicated by coagulopathy leading to thrombosis and bleeding. While venous thromboembolism (VTE) has been extensively studied, bleeding remains an underestimated threat. To address this knowledge gap, we leveraged the Epic Cosmos database to determine the impact of cancer‐associated clinically relevant bleeding (CRB) in ...
Ming Y. Lim +11 more
wiley +1 more source
Stability and Bifurcation of the Immune Model of Chronic Myeloid Leukemia with Time Delay
Journal of Harbin University of Science and TechnologyIn order to investigate the effects of the differentiation delay in chronic myeloid leukemia stem cells on the dynamic behaviors among chronic myeloid leukemia stem cells, chronic myeloid leukemia mature cells and effector T cells, a delayed immune ...
WANG Jingnan, SUN Yue
doaj +1 more source
American Journal of Hematology, EarlyView.ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima +48 more
wiley +1 more source
Angewandte Chemie, EarlyView.The carbocyclic Decitabine analog (cAzadC) incorporates as an antimetabolite weakly into the genome of growing tumor cells, where it triggers a genome‐wide demethylation and a surprisingly strong hydroxymethylation of cytosine, which translates into an efficient in vivo antitumor (AML) effect.
Maike Däther +17 more
wiley +2 more sources
Journal of the National Comprehensive Cancer Network, 2011 Margaret R, O'Donnell +19 more
openaire +2 more sources
American Journal of Hematology, EarlyView.ABSTRACT Quizartinib is a tyrosine kinase inhibitor with single agent activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and has demonstrated efficacy in first‐line therapy when combined with intensive chemotherapy in both FLT3 ITD‐negative and positive AML.
Teresa Bernal +29 more
wiley +1 more source
American Journal of Hematology, EarlyView.ABSTRACT Dordaviprone is a first‐in‐class small‐molecule imipridone. In preclinical studies, it is active against leukemia cells harboring a TP53 mutation or complex karyotype and leukemia stem cells while sparing normal bone marrow cells. This study aimed to determine the safety of dordaviprone maintenance after allogeneic hematopoietic cell ...
Vijaya Raj Bhatt +8 more
wiley +1 more source
Hepatology, EarlyView., 2022 KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou +15 more
wiley +1 more source